Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

bioAffinity Technologies (BIAF) Long-Term Debt Repayments (2022 - 2023)

bioAffinity Technologies has reported Long-Term Debt Repayments over the past 2 years, most recently at $42334.0 for Q3 2023.

Quarterly Long-Term Debt Repayments rose 161.9% to $42334.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $576746.0 through Sep 2023, changed N/A year-over-year, with the annual reading at $425000.0 for FY2022, N/A changed from the prior year.
Long-Term Debt Repayments was $42334.0 for Q3 2023 at bioAffinity Technologies, down from $126096.0 in the prior quarter.
Over five years, Long-Term Debt Repayments peaked at $325000.0 in Q4 2022 and troughed at -$68388.0 in Q3 2022.